Literature DB >> 10513759

Validation of the Agency for Health Care Policy and Research (AHCPR) classification for managing unstable angina.

C Brotons1, G Permanyer-Miralda, F Calvo, M Campreciós, M T Santos, P Cascant, I Moral, A Ribera, J Soler-Soler.   

Abstract

To validate the AHCPR classification for the prognosis of unstable angina, 225 consecutive patients were recruited with a suspected diagnosis of that condition attending a tertiary hospital from November 1994 through April 1995 and followed for one year. One-hundred fifty-six (69.3%) patients were considered at high risk, 37 (16.5%) at intermediate, and 32 (14.2%) at low risk of cardiac complications. All of the patients with major in-hospital cardiac complications (8 patients) had at least one of the features of the high risk group. The high to intermediate-low hazard ratio (HR) for one-year cardiac complications after the onset of unstable angina was 4.03. Predictors of major complications (myocardial infarction or death) after the follow-up were age > 65 (HR, 5.69); diabetes (HR, 4.94); heart failure (HR, 2.65); and prolonged angina (HR, 2.55). AHCPR classification correctly identified patients with risk of severe outcomes at the hospital. Also, the classification predicted outcomes one year after hospitalization, diabetes being an important determinant of adverse cardiac events.

Entities:  

Mesh:

Year:  1999        PMID: 10513759     DOI: 10.1016/s0895-4356(99)00117-1

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  1 in total

1.  Clinical risk stratification in the emergency department predicts long-term cardiovascular outcomes in a population-based cohort presenting with acute chest pain: primary results of the Olmsted county chest pain study.

Authors:  Michael E Farkouh; Ashish Aneja; Guy S Reeder; Peter A Smars; Sameer Bansilal; Ryan J Lennon; Heather J Wiste; Louai Razzouk; Kay Traverse; David R Holmes; Verghese Mathew
Journal:  Medicine (Baltimore)       Date:  2009-09       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.